# An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

> **NCT01001611** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 173 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** CKD-501 0.5mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01001611
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2013-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001611, "An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01001611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*